Vermillion, Inc., a molecular diagnostics company, announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent entitled "Saposin D and Fam3C are Biomarkers for Alzheimer's disease." The patent claims cover the biomarkers saposin D and Fam3c as well as combinations that include these biomarkers.

"This patent allowance is very significant as it helps create a unique asset for the company and expands our intellectual property portfolio for Alzheimer's disease. It is our goal to explore business opportunities and leverage our intellectual property in these different disease areas," said Gail S. Page, CEO of Vermillion.

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients.